Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Xiaoqiang Sun 1, 2, 3 , Jiguang Bao 4 , Zhuhong You 5 , Xing Chen 6 , Jun Cui 3, 7 1 Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510080, China 2 School of Mathematical and Computational Science, Sun Yat-Sen University, Guangzhou, 510000, China 3 School of Life Science, Sun Yat-Sen University, Guangzhou, 510275, China 4 School of Mathematical Sciences, Beijing Normal University, Beijing, 100875, China 5 School of Computer Science and Technology, China University of Mining and Technology, Xuzhou, 221116, China 6 School of Information and Electrical Engineering, China University of Mining and Technology, Xuzhou, Jiangsu, 221116, China 7 Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University, Guangzhou, 510060, China Correspondence to: Xiaoqiang Sun, email: xiaoqiangsun88@gmail.com , dongbusun@163.com Xing Chen, email: xingchen@amss.ac.cn Jun Cui, email: cuij5@mail.sysu.edu.cn Keywords: signaling crosstalk, drug resistance, drug combination, synergism Received: June 16, 2016 Accepted: August 26, 2016 Published: August 31, 2016 ABSTRACT The efficacy of pharmacological perturbation to the signaling transduction network depends on the network topology. However, whether and how signaling dynamics mediated by crosstalk contributes to the drug resistance are not fully understood and remain to be systematically explored. In this study, motivated by a realistic signaling network linked by crosstalk between EGF/EGFR/Ras/MEK/ERK pathway and HGF/HGFR/PI3K/AKT pathway, we develop kinetic models for several small networks with typical crosstalk modules to investigate the role of the architecture of crosstalk in inducing drug resistance. Our results demonstrate that crosstalk inhibition diminishes the response of signaling output to the external stimuli. Moreover, we show that signaling crosstalk affects the relative sensitivity of drugs, and some types of crosstalk modules that could yield resistance to the targeted drugs were identified. Furthermore, we quantitatively evaluate the relative efficacy and synergism of drug combinations. For the modules that are resistant to the targeted drug, we identify drug targets that can not only increase the relative drug efficacy but also act synergistically. In addition, we analyze the role of the strength of crosstalk in switching a module between drug-sensitive and drug-resistant. Our study provides mechanistic insights into the signaling crosstalk-mediated mechanisms of drug resistance and provides implications for the design of synergistic drug combinations to reduce drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862
Drug–target interaction prediction: databases, web servers and computational models
Chen, X., Yan, C. C., Zhang, X., Zhang, X., Dai, F., Yin, J., & Zhang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv066 · Cited by 658 · cited 1×
“Therefore, to both synergistically and effectively reduce drug resistance, it’s important to select drug targets in the signaling network for rationally designing optimal drug combinations [29, 31, 32].”
BackgroundSelf-citationDrug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555
Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478
Poised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301
Mao, M., Tian, F., Mariadason, J. M., Tsao, C. C., Lemos, R., Dayyani, F., Gopal, Y. N. V., Jiang, Z.-Q., Wistuba, I. I., Tang, X. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1446 · Cited by 290 · cited 1×
“The predicted synergistic effect of combination of B-targeting drug and D-targeting drug for module 4 is consistent with experimental studies [48, 49].”
ResultSynergistic and Antagonistic Drug Combinations Depend on Network Topology
Yin, N., Ma, W., Pei, J., Ouyang, Q., Tang, C., & Lai, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093960 · Cited by 139 · cited 1×
“[30], the synergism or antagonism of drug combinations largely depends on the network topology.”
Background
Cited by
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx806 · Cited by 653
Computational Approaches in Theranostics: Mining and Predicting Cancer Data
Cova, T. F. G. G., Bento, D. J., & Nunes, S. C. C. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030119 · Cited by 32
PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
Davis, T. B., Yang, M., Wang, H., Lee, C., Yeatman, T. J., & Pledger, W. J. (2019) · Oncotarget · doi:10.18632/oncotarget.27335 · Cited by 11
Metadata
- Authors
- Sun, X., Bao, J., You, Z., Chen, X., & Cui, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-08-31
- Volume
- 7
- Issue
- 39
- Pages
- 63995-64006
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2518259126
- Cited by
- 60
- References
- 7
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.